Business Irish

Thursday 14 December 2017

TCD drug firm gets €6m EU grant

John Mulligan

OPSONA THERAPEUTICS -- a drug development firm founded in Trinity College -- has been awarded a grant of almost €6m by the European Commission to advance clinical trials for a promising treatment for kidney transplant patients.

The grant is the largest ever awarded under the EU's FP7 programme, which funds collaborative clinical trials.

Opsona will lead a European consortium of research and clinical groups for its OPN-35 drug.

The first trial of the treatment is due to begin this summer. Following successful completion of that trial, the consortium plans to conduct a phase 2 trial, commencing in 2012.

The initial trial will focus on the use of OPN-35 in addressing what's called 'delayed graft function' -- a serious complication of the immediate postoperative period in renal transplantation.

The company hopes the drug may have commercial potential for the treatment of a broad range of human diseases, including cancer and cardiovascular disease.

Opsona is backed by Dublin-based venture capital fund Fountain Healthcare Partners, as well as Novartis Venture Fund and Enterprise Ireland.

Irish Independent

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business